Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
LY6G6D is a member of the lymphocyte antigen 6 superfamily, expressed in leukocytes and selectively upregulated in colorectal cancer. It plays a key role in neutrophil migration and infiltration and is implicated in immune senescence. It is a therapeutic target for colorectal cancer, particularly via T-cell engagers, but potential safety concerns include bystander killing of non-target cells.
T-cell redirection to kill CRC cells (via T-cell engagers)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Lymphocyte Antigen 6 Complex Locus G6D (LY6G6D).